NYSE:EWMedical Equipment
How New Structural Heart Data from TAVR and PASCAL Will Impact Edwards Lifesciences (EW) Investors
Earlier this week, Edwards Lifesciences reported new clinical data at the New York Valves 2026 conference, including PROGRESS trial baseline results in moderate aortic stenosis and long-term SAPIEN 3 performance, alongside real-world outcomes for its mitral and tricuspid therapies such as PASCAL and SAPIEN M3.
The breadth of evidence across aortic, mitral and tricuspid therapies offers investors fresh insight into how Edwards is building a data-rich structural heart portfolio that could...